- Home
- SOS vs BLRX Comparison
SOS vs BLRX Comparison
Compare SOS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOS
- BLRX
- Stock Information
- Founded
- SOS 2004
- BLRX 2003
- Country
- SOS China
- BLRX Israel
- Employees
- SOS N/A
- BLRX N/A
- Industry
- SOS Finance: Consumer Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- SOS Finance
- BLRX Health Care
- Exchange
- SOS Nasdaq
- BLRX Nasdaq
- Market Cap
- SOS 18.2M
- BLRX 17.0M
- IPO Year
- SOS 2017
- BLRX 2011
- Fundamental
- Price
- SOS $2.47
- BLRX $3.87
- Analyst Decision
- SOS
- BLRX Strong Buy
- Analyst Count
- SOS 0
- BLRX 2
- Target Price
- SOS N/A
- BLRX $19.00
- AVG Volume (30 Days)
- SOS 197.6K
- BLRX 35.0K
- Earning Date
- SOS 09-23-2025
- BLRX 08-14-2025
- Dividend Yield
- SOS N/A
- BLRX N/A
- EPS Growth
- SOS N/A
- BLRX N/A
- EPS
- SOS N/A
- BLRX N/A
- Revenue
- SOS $231,424,000.00
- BLRX $22,340,000.00
- Revenue This Year
- SOS N/A
- BLRX N/A
- Revenue Next Year
- SOS N/A
- BLRX N/A
- P/E Ratio
- SOS N/A
- BLRX N/A
- Revenue Growth
- SOS 150.42
- BLRX 91.68
- 52 Week Low
- SOS $2.25
- BLRX $2.30
- 52 Week High
- SOS $15.51
- BLRX $35.02
- Technical
- Relative Strength Index (RSI)
- SOS 22.67
- BLRX 36.06
- Support Level
- SOS $6.77
- BLRX $4.47
- Resistance Level
- SOS $7.14
- BLRX $4.32
- Average True Range (ATR)
- SOS 0.68
- BLRX 0.27
- MACD
- SOS -0.67
- BLRX -0.08
- Stochastic Oscillator
- SOS 3.28
- BLRX 15.38
About SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.